Data presented at the American Society of Clinical Oncology (ASCO) reinforce enthusiasm for a new approach being developed by companies including Elevation Oncology (Nasdaq: ELEV).
Results from an early-stage study of the firm's anti-Claudin18.2 candidate EO-3021 reveal a well-tolerated safety profile for people with difficult to treat cancers.
Elevation is following in the footsteps of Japanese drug major Astellas Pharma (TYO: 4503), which has attracted significant interest after positive late-stage data for its antibody zolbetuximab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze